hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses.. JCO ...
[27]Bedard PL, Jhaveri K, Cervantes A, et al. Abstract PD1-02: a phase I/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptorpositive/HER2-n...
Epub 2015 Dec 1. PMID: 26627007; PMCID: PMC4681596. [8]Cho YB, Park KS. The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future Directions. Medicina (Kaunas). 2025 Mar 17;61(3):518. doi: 10.3390/medicina61030518. PMID: 40142329....
此前，Breast Cancer Research And Treatment杂志在线发表了一项荟萃分析结果，通过整合既往研究数据，探索了了PIK3CA突变状态在原发性与转移性乳腺癌间的不一致性，该结果对于优化治疗方案、提高治疗效果具有重要意义[6]。医学界特邀江南大学附属医院张颖教授详细解读该研究，现攫取重要内容整理如下，以飨读者。图1 研究标...
[6]Buono, G., Gerratana, L., Bulfoni, M., et al. (2019). Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. Cancer treatment reviews, 73, 73–83.[7]Gerratana, L., Davis, A. A., Velimirovic, M., et al. (2023). Interplay between ESR1/PIK3CA ...
Cancer Res. 2015 Dec 15;75(24):5341-54. doi: 10.1158/0008-5472.CAN-15-1654. Epub 2015 Dec 1. PMID: 26627007; PMCID: PMC4681596.[8]Cho YB, Park KS. The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future Directions. Medicina (Kaunas). 2025 Mar...
Several combination therapies based on PI3K inhibition have been proposed, but a way to systematically prioritize them for breast cancer treatment is still missing. By integrating published and in-house studies, we have developed in silico models that quantitatively capture dynamics of PI3K signaling ...
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2. Br J Cancer. 2017;116:726-30.Moynahan ME; Chen D; He W;.Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2...
6.https://novartis.gcs-web.com/FDA-approves-Novartis-Piqray-the-first-and-only-treatment-specifically-for-patients-with-a-PIK3CA-mutation-in-HRHER2-advanced-breast-cancer 本站仅提供存储服务,所有内容均由用户发布,如发现有害或侵权内容,请
2. O. Al Jarroudi et al. Breast Cancer Research and Treatment, Cancer Treatment and Research 188 3. Breast Cancer Expert Committee of the National Quality Control Center for Cancer, et al. Cancer Innov. 2025 Apr 9...